On November 10, 2021, the CDE (Center for Drug Evaluation) under the NMPA (National Medical Products Administration) published the annual report on clinical trial applications for new drug products registered in 2020. The online drug platform received a total of 2602 clinical trial applications in 2020 with an increase of 9.1% as compared to 2019.
According to the report, 1473 applications were for new drugs and 1129 applications were for generic drugs. Under the new drug category, 801 applications (73.6%) were for chemical drugs, 605 applications (23.8%) were for biological products, and 67 applications (4.5%) were chinese medicine and natural drug products.
Although the report points out problem such as homogenization in drug clinical trials, inefficient implementation of clinical trials after approvals, etc., there is still an increasing demand of clinical trial applications for drugs in China.
By Sun Jinlin and Jacky Li. Contact Cisema if you would like to learn more.
